Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have measurable or evaluable urothelial cancer.~  * Measurable disease includes unresectable or metastatic urothelial tract tumors that are unidimensionally measurable by xray,CT/MRI scan or physical examination.~ * Evaluable disease is restricted to patients with unresectable primary bladder tumors which can be evaluated for response by cystoscopy.~* Pathologic confirmation by the Department of Pathology at MSKCC.~* Karnofsky Performance Status (KPS) ≥60%.~* Adequate marrow function defined as granulocytes ≥ 1500 cells/mm 3 , platelets ≥ 100,000 cells/mm 3 , and hemoglobin ≥ 8.0 g/dl.~* Serum creatinine \< 2.0 mg/dl~* 24-hour urine sample demonstrating creatinine clearance ≥ 60 ml/min/1.73m2 or calculated creatinine clearance ≥ 60 ml/min/1.73m 2 using the formula: Jeliffe Equation: estimated creatinine clearance = 98 x (0.8 \[age(yrs) 20\]/Serum Creatinine (mg/dL) x (0.9 if Female))~* Adequate hepatic function defined as:~  * Total Bilirubin \< or = to 1.5 x ULN~ * AST and ALT \< or = to 3.0 x ULN (\< or = to 5.0 x ULN is acceptable if liver has tumor involvement)~* Normal coagulation profile including PT/INR and PTT, unless patient is receiving anticoagulation therapy with agents such as warfarin or heparin.~* Age ≥ 18 years~* Informed consent~* Women of childbearing potential must have a negative pregnancy test.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.~* Patients are encouraged to continue barrier method contraception for two years or longer after treatment.~Exclusion Criteria:~* Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted).~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.~* Blood Pressure of \> 150/100 mm Hg.~* Irradiation within 4 weeks of start of protocol.~* Evidence of another active cancer, except for nonmelanoma skin carcinoma, insitu carcinoma of the cervix curatively treated, and adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is nondetectable.~* Significant cardiovascular disease including congestive heart failure (New York Heart Association Class II or higher) or active angina pectoris.~* History of a myocardial infarction within 6 months.~* History of a stroke or transient ischemic attack within 6 months.~* Clinically significant peripheral vascular disease.~* Evidence of bleeding diathesis or coagulopathy.~* Presence of central nervous system or brain metastases.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0.~* Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0.~* History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to Day 0.~* Serious nonhealing wound, ulcer, or bone fracture.~* History of persistent gross hematuria.~* Uncontrolled infection.~* Hypersensitivity to sorafenib, or any component of the formulation.~* Pregnant (positive pregnancy test) or lactating.~* Inability to comply with the study and/or followup procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.

Based on this trial design, predict the completion outcome and termination type (if applicable).